Q2 2021 13F Holders as of 6/30/2021
-
Type / Class
-
Equity / Common Stock, $0.00001 par value per share
-
Shares outstanding
-
164M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
55.8M
-
Shares change
-
+1.41M
-
Total reported value, excl. options
-
$353M
-
Value change
-
-$141K
-
Put/Call ratio
-
2.43
-
Number of buys
-
63
-
Number of sells
-
-49
-
Price
-
$6.33
Significant Holders of CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) as of Q2 2021
137 filings reported holding CTMX - CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share as of Q2 2021.
CytomX Therapeutics, Inc. - Common Stock, $0.00001 par value per share (CTMX) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 55.8M shares
of 164M outstanding shares and own 34% of the company stock.
Largest 10 shareholders include Point72 Asset Management, L.P. (6.39M shares), VANGUARD GROUP INC (5.36M shares), BlackRock Inc. (5.08M shares), STATE STREET CORP (4.62M shares), RA CAPITAL MANAGEMENT, L.P. (3.5M shares), VICTORY CAPITAL MANAGEMENT INC (2.87M shares), Candriam Luxembourg S.C.A. (2.33M shares), PERCEPTIVE ADVISORS LLC (1.64M shares), ORBIMED ADVISORS LLC (1.51M shares), and JACOBS LEVY EQUITY MANAGEMENT, INC (1.41M shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.